FDA Clears Philips Wearable Light Therapy Device for Psoriasis Treatment
13 Julho 2017 - 11:02AM
Dow Jones News
By Razak Musah Baba
LONDON--Royal Philips NV (PHIA.AE) has received U.S. Food and
Drug Administration clearance to market its Philips BlueControl, a
wearable light therapy device to treat mild psoriasis at home.
The Dutch health-technology company obtained Europe's CE marking
for the device in 2015 and has been selling it in European
countries such as Germany and the U.K.
Following the FDA clearance, Philips said it would start talking
with dermatologists and patient support groups in the U.S. and
prepare for the commercial launch of BlueControl there in early
2018.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
(END) Dow Jones Newswires
July 13, 2017 09:47 ET (13:47 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Koninklijke Philips NV (EU:PHIA)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Koninklijke Philips NV (EU:PHIA)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024